CN110423275A - A kind of G-17 monoclonal antibody and its application - Google Patents
A kind of G-17 monoclonal antibody and its application Download PDFInfo
- Publication number
- CN110423275A CN110423275A CN201910031620.4A CN201910031620A CN110423275A CN 110423275 A CN110423275 A CN 110423275A CN 201910031620 A CN201910031620 A CN 201910031620A CN 110423275 A CN110423275 A CN 110423275A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- antibody
- glu
- gastrin
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a kind of G-17 monoclonal antibody, it is IgG type, is prepared by monoclonal cell strain S100 and S200, cell strain S100 is preserved in Chinese Typical Representative Organism Depositary, preservation date on January 15th, 2019, deposit number CCTCC M 2019010；Cell strain S200 is preserved in Chinese Typical Representative Organism Depositary, preservation date on January 15th, 2019, deposit number CCTCC M 2019020.Monoclonal antibody includes GC-1 and GN-1, and using antibody GN-1 as coated antibody, GC-1 establishes DAS-ELISA method as labelled antibody, detects the G-17 content in natural sera.The beneficial effects of the present invention are: this monoclonal antibody is capable of the combination G-17 of specificity, and recognition capability and efficiency are higher.This monoclonal antibody can be efficiently applied in medicine preparation, increase the targeting and specificity of drug.
Description
Technical field
The present invention relates to genetic engineering fields, and in particular to a kind of G-17 monoclonal antibody and its application.
Background technique
Gastrin is a kind of important gastrointestinal tract peptide hormone, by British scholar Edkins first discovery and is ordered in 1905
Name.Gastrin is synthesized and is secreted by the G cell for being located at antrum and duodenum proximal end mucous membrane.Its synthesis experienced by gastrin
For former, glycine extended gastrin to the stage of mature gastrin, the intermediate product of first two gastrin synthesis is non-amidation
Gastrin, and mature gastrin is amidated gastrin, and 95% or more active gastrin is that α-amide stomach is secreted in human body
Element.Amidated gastrin includes G17, G34, G14, G6, G52, G71, and wherein G17 is the principal mode of gastrin in antrum, is
Into the principal mode of gastrin in post-prandial blood, G34 is the principal mode of gastrin in duodenum, is the stomach between two meal
The principal mode of secretin.Gastrin in conjunction with gastrin-receptor after by a series of signal transduction play biological effect.Stomach
Secretin and cholecystokinin five peptide sequence of carboxyl terminal having the same, therefore its receptor and cholecystokinin receptor
(cholecystokinin receptor, CCKR) is identical, therefore gastrin-receptor is also referred to as CCKR.CCKR mainly has CCK-A
Receptor and two kinds of CCK-B receptor, gastrin mainly passes through plays biological effect in conjunction with CCK-B receptor.
In atrophic gastritis (chronic atrophic gastritis, CAG), serum G17 withers with stomach lining
Contracting position and atrophy degree have correlation.Cao etc. has found the serum G17 ratio of antrum atrophy group in a case-control study
Control group is low, and the serum G17 of corpus atrophy group is higher than control group, and the serum G17 of multifocal atrophy group is lower than control group, but is higher than
Antrum group.Its reason is analyzed when may be for antrum atrophy, G cell quantity is less, and G17 synthesis reduces；When corpus atrophy, secrete sour thin
Born of the same parents' quantity is reduced, and low acid condition is in stomach, causes gastrin to increase by gastrin gastric acid axis negative-feedback.The researchs such as model Yulin will
Stomach lining is light, neutralizes severe atrophy group respectively compared with Normal group, and serum G17 content is shown in the slight atrophy of stomach lining
Work increases, and without significant difference when moderate atrophy, when severe atrophy is significantly reduced；Compared with Normal group, G cell quantity is in stomach
Without significant difference when atrophy that mucous membrane is slight.And it is then significantly reduced in stomach lining, when severe atrophy.
During patient send out currently all in old equal researchs, compared with non-atrophic gastritis group, gastric ulcer group serum G17 level
It is significant to increase (P < 0.05).It opens the loyal equal G17 level by 3906 parts of blood serum samples and detects discovery, by normal person through shallow
Gastritis to gastric erosion or ulcer, the horizontal progressive of serum G17 increases.Raising may there are inflammation with stomach lining for serum G17 level
Reaction and gastric erosion ulcers mostly infect with H.pylori related.
The level of Serum Obtained From Advance Gastric Cancer G17 is related to diseased region, clinical stages, pathological tissue parting.In 164 gastric cancers
In patient, it is divided into gastric cancer group, body of stomach cancer group, the total Gastrin Levels of serum are detected at stomach bottom, cardia cancer group, the results showed that, stomach
Bottom, cardia cancer level of serum gastrin be much higher than body of stomach cancer, gastric cancer and Normal group, and as gastric cancer clinical stages, gets over
Come higher；Body of stomach cancer-serum Gastrin Levels group is higher than control group, and gastric cancer group is then lower than control group, but the two difference is without statistics
Learn meaning.Stomach bottom, cardia cancer and body of stomach cancer-serum G17 are significantly raised, it may be possible to due to cancerous tissue considerable damage secrete acid gland body and
Vagus nerve ending lacks gastric acid secretion, and level of serum gastrin feedback increases.Konturek etc. measures 72 gastric cancer groups
With the serum gastrin of 77 control groups, as a result, it has been found that, gastric cancer group serum gastrin be higher than control group, the high stomach of intestinal-type gastric cancer group
Secretin mass formed by blood stasis patient is significantly more than diffusion-type, mixed type gastric cancer group, has gastrin participation in the occurrence and development of research confirmation gastric cancer,
It has certain meaning to the growth of cancer cell and vicious transformation.Gastrin has with the CCK-2 receptor in upper alimentary tract mucosa
High affinity, in conjunction with after can many A signal pathways such as active cell proliferation, anti-apoptotic, inflammatory reaction, induce acid secretion with
And promote tumour.Morton etc. establishes high gastrin animal model, it is found that vicious transformation occurs for its Gastric Mucosal Cells.
Takaishi etc. proposes that H.pylori infection is the starting of gastric cancer when studying the relationship of gastric cancer and H.pylori and gastrin
Factor, and gastrin is the important factor for promoting stomach cancer development.
Summary of the invention
In order to detect the G-17 content in natural sera, we have proposed a kind of G-17 monoclonal antibody and its applications.This
Invention is achieved through the following technical solutions:
The present invention provides a kind of G-17 monoclonal antibody, and monoclonal antibody is IgG type, by monoclonal cell strain S100 and
S200 is prepared, and cell strain S100 is preserved in Chinese Typical Representative Organism Depositary, preservation date on January 15th, 2019, is protected
Hide number CCTCC M 2019010；Cell strain S200 is preserved in Chinese Typical Representative Organism Depositary, and preservation date 2019 1
The moon 15, deposit number CCTCC M 2019020.
Preferably, said monoclonal antibody includes GC-1 and GN-1, and wherein GC-1 is prepared by S100, and GN-1 is by S200
It prepares.
Present invention simultaneously provides a kind of applications of G-17 monoclonal antibody, using antibody GN-1 as coated antibody, GC-1
As labelled antibody, DAS-ELISA method is established, detects the G-17 content in natural sera.
Preferably, the amino acid sequence of above-mentioned GC-1 are as follows:
Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2。
Preferably, the amino acid sequence of above-mentioned GN-1 are as follows: Pro-Glu-Gly-Pro-Trp-Leu-Glu-Glu.
Preferably, the parting of above-mentioned GC-1 is IgG2a.
Preferably, the parting of above-mentioned GN-1 is IgG1.
Compared with prior art, the beneficial effects of the present invention are:
(1) monoclonal antibody of the present invention is capable of the combination G-17 of specificity, and recognition capability and efficiency are higher.
(2) monoclonal antibody of the present invention can be efficiently applied in medicine preparation, increase drug targeting and
Specificity.
Specific embodiment
Below with reference to embodiment, the content of the present invention will be explained in more detail.It should be appreciated that implementation of the invention is not limited to
In the following examples, the accommodation in any form or change made to the present invention both fall within the scope of the present invention；Under and
The method in embodiment is stated, is the conventional method of this field unless otherwise instructed.
Embodiment 1:
One, the acquisition of hybridoma and its preparation of monoclonal antibody
1. animal immune
Immunogene is recombinant antigen, purchased from scientific and technological (Nanjing) Co., Ltd of Jin Sikang, article No. be PE2594 (GN) and
PE2595(GC).The amino acid sequence of GN are as follows:
Pro-Glu-Gly-Pro-Trp-Leu-Glu-Glu；The amino acid sequence of GC are as follows:
Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2.6 week old weight are immunized with this recombinant protein
The BALB/c female mice of 18-20g.That is 100 μ g/ of G-17 recombinant protein is only mixed with Freund's complete adjuvant, after fully emulsified, warp
Carry on the back subcutaneous abdomen multi-point injection 0.3mL/ only, after at interval of 2 weeks, take 80 μ g/ antigens and freund 's incomplete adjuvant fully emulsified
Afterwards, only, the 4th is immunized after a week in intraperitoneal injection 0.3mL/, carries out eyeball to mouse and takes blood, detects serum titer, take potency
Reach 1:105Or more mouse carry out spleen booster immunization, when spleen be immunized, recombinant antigen amount is 30 μ g/, is taken after 3 days
Splenocyte carries out cell fusion.
2. the preparation of feeder cells
It takes BALB/c mouse peritoneal macrophage and thymocyte as feeder cells, the specific operation method is as follows: taking
BALB/c mouse, eyeball bloodletting is lethal, after 75% alcohol impregnates body surface disinfection, with after disinfection scissors and tweezers cut off from rear abdomen
Skin of abdomen, exposure peritonaeum.It takes 4ml IMDM culture medium to abdominal cavity with syringe, gently squeezes abdomen with finger, and carry out anti-
It is multiple to rinse, recycle flushing liquor.The thymus gland for taking out mouse is rinsed after being pulverized with IMDM culture medium, recycles washing lotion.It will return twice
After receiving liquid mixing, 1200rpm is centrifuged 3min, abandons supernatant to get feeder cells are arrived.
3. cell fusion
Immune mouse spleen cell and murine myeloma cell (SP2/0) is taken to cultivate in the ratio of 7:1 in the IMDM of serum-free
It is mixed in base, 1300rpm is centrifuged 3min, removes culture medium, and 1mL 50%PEG (molecular weight 1500) is added simultaneously in 37 DEG C of water-baths
2min is merged, 1300rpm is centrifuged 3min after terminating fusion with the IMDM culture medium of serum-free, and precipitating is suspended with HAT culture medium, and
Feeder cells are added, is dispensed into 96 holes and contains in the cell plates of feeder cells, be placed in 37 DEG C, contain 5%CO2Cell culture
It is cultivated in case.
4. screening and its clone of hybridoma
After being cultivated 5 days in cell incubator, until fused cell covers bottom hole 10-30%, with conventional indirect ELISA side
Method screens the positive hole of secretory antibody, i.e., using G-17 recombinant protein as antigen, is diluted to 0.5 μ g/ml with CB and is coated with 96 hole enzyme marks
Plate, 50 holes μ l/, 4 DEG C of coatings overnight, after patting dry, close (200 hole μ l/) with the PBS buffer solution containing 1%BSA, 37 DEG C of closings 2
Hour, it pats dry spare；50 hole μ l/ of cells and supernatant to be checked is added in above-mentioned elisa plate, is washed after 37 DEG C of reaction 30min
It washs and pats dry, the sheep anti-mouse igg of the HRP label in 50 holes μ l/ is added, washs and pats dry after 37 DEG C of incubation 30min, 50 μ are added
The TMB developing solution in the hole l/ is protected from light colour developing 10min in 37 DEG C, the 2M H in 25 holes μ l/ is added2SO4Reaction is terminated, and at 0D450
Reading numerical values.The determination principle in positive hole: OD450 value/negative control value >=2:1.Selection is in the cell hole of strong positive reaction,
Carry out limiting dilution assay clone.After three to four cloning screenings, monoclonal cell strain positive rate 100% is determined as
Stable cell line.After expanding culture, for ascites preparation and Liquid nitrogen storage.Two plants of monoclonal cell strains be denoted as respectively S100 and
S200。
5. the preparation of monoclonal antibody ascites and purifying
8 week old or so F1 mouse is taken, 0.3-0.5mL paraffin is injected intraperitoneally, after 7-10 days Intraperitoneal injection 8 × 105A hybridization
Oncocyte, 7-10 days visible mouse web portions obviously expand after injection, and injection needle takes ascites, and 8000rpm is centrifuged 3min, collect
Supernatant is odd contradictive hydroperitoneum.1 times of volume ascites is taken to add 2 times of 4.8 acetate buffer solution of volume 0.06M pH dilutions, room temperature is following
Stirring side adds sad (30 μ L/mL ascites), and 4 DEG C of clarifications 1h, 12000rpm are centrifuged 20min, collects supernatant, then be saturated with 50%
Ammonium sulfate precipitation immunoglobulin, 4 DEG C of placements 2h, 3000rpm are centrifuged 20min, and the PBS solution of 2 times of volumes of precipitating dissolves, In
4 DEG C of flowing dialysis obtain the ascites antibody of purifying, -70 DEG C of preservations afterwards for 24 hours.
Two, the screening preparation of antibody is matched
1. the HRP label of antibody takes 1mg HRP to be dissolved in the distilled water of 0.5ml, 0.2ml NaIO4 solution is added
(0.06mol/L), mixing be placed on 4 DEG C be protected from light under the conditions of 30min.It is added 0.2ml ethylene glycol solution (0.16mol/L), room temperature
(20 DEG C or so) lower gentle agitation 30min under the conditions of being protected from light.The antibody-solutions of 1mg are added, are fitted into bag filter after mixing,
It is placed in CBS solution under the conditions of being protected from light and dialyses 6h (or 4 DEG C overnight).Reaction solution is taken out from bag filter, and 50 μ l NaBH4 are added
Solution (5mg/ml), mixing be placed in 4 DEG C be protected from light under the conditions of 2h.It is slowly added to the saturated ammonium sulfate solution of isometric (about 1.2ml),
Mixing be placed in 4 DEG C be protected from light under the conditions of 30min, 10000rpm centrifugation 10min removes supernatant, with the molten precipitating of the PBS of 200ul weight, so
It is placed in PBS the 12-18h that dialyses, is during which changed the liquid once.It takes out solution and measures volume, isometric glycerol is added, it is sufficiently mixed
It is saved backup after even in -20 DEG C.
2. coated antibody is diluted to 4 μ g/ml with CB by the screening of pairing antibody, ELISA Plate hole is added to every 100 μ l of hole
In, 4 DEG C of coatings are overnight.ELISA Plate is patted dry, 200 μ l confining liquids (PBS containing 1%BSA) are added in every hole, close 1- at 37 DEG C
2h is simultaneously patted dry.Positive blood sample is diluted to 2ng/ml with PBS, every hole is loaded 100 μ l, is control with negative blood sample.37 DEG C of incubations
Board-washing 3 times after 1h, the PBST that washing lotion is 0.05%.Enzyme labelled antibody is diluted to 1000 times of work with the washing lotion containing 1%BSA
Liquid, every hole add 100 μ l, 37 DEG C of incubation 1h, then board-washing 4 times and pat dry.100 μ l TMB developing solutions, 37 DEG C of incubations are added in every hole
10min.Every hole adds 50 μ l that terminate liquid is added, and reads OD value with 450nm in microplate reader.As a result as follows:
Three, the Performance Evaluation and relevant parameter of antibody GC-1/GN-1 are matched
1. the specific detection for matching antibody presses method for detecting specificity, the specificity of GC-1/GN-1 pairing is examined
It surveys, uses 25 parts of positive serums and 25 parts of negative serums altogether, be the positive with P/N >=2, as a result as follows:
2. the Classification Identification of monoclonal antibody
Using antibody typing identification kit SBA Clonotyping System-HRP (Southern Biotech,
Cat:5300-05), by specification method is identified.
The specific method is as follows:
1. coating: diluting capture with the borate buffer solution (BBS) of pH8.2 or the phosphate buffer (PBS) of pH7.4
Antibody to concentration is 5-10 μ g/mL, and 100 μ L are added in every hole；
2. covering ELISA Plate with lid or preservative film, at least 12h is incubated under 2-8 DEG C of moist environment；
3. closing: drying is washed 3 times with PBS or BBS containing 0.05% tween；Drying, be added PBS containing 1%BSA or
BBS, every 200 μ L of hole；
4. allowing the coated plate of antibody to stand at least 1h at room temperature, to block the binding site to dissociate on plate；
5. 100 μ L doma supernatants or detection antibody, cover board, the mild oscillation incubation 1h or 2-8 of room temperature is added in every hole
DEG C overnight；
6. washing lotion is washed 3 times；
7. 100 μ L conjugates are added in plate with the detection antibody 1:250-1:500 of BBS/BSA dilution HRP label,
Cover board, shaken at room temperature 1h or 2-8 DEG C are overnight；
8. washing lotion is washed 5 times；
9. preparing ABST Substrate stock liquid --- -- 15mgABST powder is dissolved in 1mL distilled water, guarantor is protected from light at 2-8 DEG C
It deposits, stablizes in 4 weeks；
10. preparing substrate solution --- -525mg citric acid is added in 50mL distilled water, and stirring is to being completely dissolved；Use NaOH
Adjust pH to 4.0；0.2mLABST stock solution and 10 μ L, 30% H are added into 10mL citrate buffer2O2；
100 μ L substrate buffer solutions are added in every hole；
It is read at 405nm using microplate reader.
As a result as follows.
ELISA detects OD405 and counts:
Classification Identification result:
Claims (7)
1. a kind of G-17 monoclonal antibody, which is characterized in that the monoclonal antibody is IgG type, by monoclonal cell strain S100
It being prepared with S200, cell strain S100 is preserved in Chinese Typical Representative Organism Depositary, preservation date on January 15th, 2019,
Deposit number CCTCC M 2019010；Cell strain S200 is preserved in Chinese Typical Representative Organism Depositary, and preservation date 2019
January 15, deposit number CCTCC M 2019020.
2. a kind of G-17 monoclonal antibody as described in claim 1, which is characterized in that the monoclonal antibody include GC-1 and
GN-1, wherein GC-1 is prepared by S100, and GN-1 is prepared by S200.
3. a kind of application of G-17 monoclonal antibody, which is characterized in that the monoclonal antibody is using antibody GN-1 as coating
Antibody, GC-1 establish DAS-ELISA method as labelled antibody, detect the G-17 content in natural sera.
4. a kind of application of G-17 monoclonal antibody as claimed in claim 3, which is characterized in that the amino acid sequence of the GC-1
It is classified as: Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2.
5. a kind of application of G-17 monoclonal antibody as claimed in claim 3, which is characterized in that the amino acid sequence of the GN-1
It is classified as: Pro-Glu-Gly-Pro-Trp-Leu-Glu-Glu.
6. a kind of application of G-17 monoclonal antibody as claimed in claim 3, which is characterized in that the parting of the GC-1 is
IgG2a。
7. a kind of application of G-17 monoclonal antibody as claimed in claim 2, which is characterized in that the parting of the GN-1 is
IgG1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910031620.4A CN110423275A (en) | 2019-01-14 | 2019-01-14 | A kind of G-17 monoclonal antibody and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910031620.4A CN110423275A (en) | 2019-01-14 | 2019-01-14 | A kind of G-17 monoclonal antibody and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110423275A true CN110423275A (en) | 2019-11-08 |
Family
ID=68408326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910031620.4A Withdrawn CN110423275A (en) | 2019-01-14 | 2019-01-14 | A kind of G-17 monoclonal antibody and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110423275A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112608944A (en) * | 2021-01-13 | 2021-04-06 | 杭州博岳生物技术有限公司 | Construction method and application of humanized antibody expression vector |
-
2019
- 2019-01-14 CN CN201910031620.4A patent/CN110423275A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112608944A (en) * | 2021-01-13 | 2021-04-06 | 杭州博岳生物技术有限公司 | Construction method and application of humanized antibody expression vector |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ellis et al. | Monoclonal antibody preparation and purification of a tumor cell collagenasestimulatory factor | |
| CN105112375B (en) | Hybridoma cell strain ZJED0-02, anti-Ebola virus GP protein monoclonal antibody and its preparation and application | |
| CN102816235B (en) | Preparation method of hybrid tumor of monoclonal antibody inhibiting common bacillus thuringiensis CryI, and application of monoclonal antibody thereof | |
| CN109311983A (en) | Anti- CLEVER-1 antibody of humanization and application thereof | |
| CN101921731A (en) | Monoclonal antibody of fluoroquinolone medicines as well as preparation method and application thereof | |
| JPH02488A (en) | Antihuman bcdf monmoclonal antibody | |
| CN102180969A (en) | Monoclonal antibody with liver cancer resisting activity and application thereof | |
| EP0657471A1 (en) | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours | |
| CN103849604B (en) | Hybridoma cell strain ST03, anti-aflatoxin biosynthesis precursor ST monoclonal antibody and application thereof | |
| CN102703388A (en) | Anti-human mCRP (monomeric C-reaction protein) monoclonal antibody, hybridoma cell lines and kit | |
| CN110423275A (en) | A kind of G-17 monoclonal antibody and its application | |
| CN108048407A (en) | The monoclonal antibody of hybridoma cell strain and anti-human CTRP3 and its application | |
| CN108503709A (en) | A kind of preparation and application of the monoclonal antibody of anti-Cas9 albumen | |
| CN101481724A (en) | Preparation and use of antibacterial peptide PMAP-23 monoclonal antibody | |
| CN112062846A (en) | G-17 monoclonal antibody and application thereof | |
| CN103266089A (en) | Anti-human copeptin monoclonal antibody mcco1 and application thereof | |
| CN109762058A (en) | A kind of preparation recombinating G-17 albumen and its monoclonal antibody | |
| CN104745536B (en) | A kind of toxoplasma protein TgVP1 monoclonal antibody hybridomas 3A6 and monoclonal antibody | |
| CN104745535B (en) | A kind of toxoplasma protein TgVP1 monoclonal antibody hybridomas 1D7 and monoclonal antibody | |
| CN102818896A (en) | Detection method of nitration modification sites based on specific antibodies and antibody capable of specifically recognizing succinyl-CoA: 3-oxoacid CoA transferase (SCOT) nitration sites | |
| CN110205302B (en) | Cell strain secreting monoclonal antibody against mycophenolic acid, monoclonal antibody and application thereof | |
| CN108795878A (en) | Secrete anti-CST1 monoclonal antibody hybridoma cells strain and its monoclonal antibody and application | |
| JP3581160B2 (en) | Anti-mucus glycoprotein monoclonal antibody | |
| JPH06153979A (en) | Monoclonal antibody against fish iridovirus, hybridoma for producing the antibody and production method | |
| CN102549014A (en) | Human serum amyloid-A3 antibody and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191108 |
|
| WW01 | Invention patent application withdrawn after publication |